Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID R CAMIDGE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1336239912
CMS profile
241703
Location
AURORA, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$142,330.66

61 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $42,812.50 10
EMD Serono, Inc. $27,645.00 4
Takeda Pharmaceuticals U.S.A., Inc. $15,155.78 5
Eli Lilly and Company $9,843.29 12
GENZYME CORPORATION $9,019.00 3
PFIZER INC. $7,200.00 3
Lilly USA, LLC $6,562.50 3
Amgen Inc. $6,325.00 5
Seagen Inc. $3,600.00 4
Janssen Research & Development, LLC $2,295.00 1
GlaxoSmithKline, LLC. $2,275.00 1
Genentech USA, Inc. $2,195.00 1
Janssen Global Services, LLC $1,890.00 1
Eisai Inc. $1,875.00 1
F. Hoffmann-La Roche AG $1,815.00 1
E.R. Squibb & Sons, L.L.C. $625.00 3
Helsinn Healthcare SA $625.00 1
AbbVie Inc. $550.00 1
Novartis Pharmaceuticals Corporation $22.59 1

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID R CAMIDGE

NPI 1336239912 · CMS profile ID 241703

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

AURORA, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336239912?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID R CAMIDGE, NPI 1336239912, CMS profile ID 241703. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336239912?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID R CAMIDGE, NPI 1336239912, CMS profile ID 241703. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336239912?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID R CAMIDGE, NPI 1336239912, CMS profile ID 241703, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1336239912?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

61 matching records · $142,330.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 61 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–61 of 61.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $25.0002/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728398295 CMS
Eli Lilly and Company $3.0002/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728401751 CMS
Eli Lilly and Company $3.8502/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728408557 CMS
Eli Lilly and Company $20.6602/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728408559 CMS
Daiichi Sankyo Inc. $4,531.2502/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739473331 CMS
EMD Serono, Inc. $4,850.0002/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751287917 CMS
Daiichi Sankyo Inc. $1,250.0001/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739478129 CMS
E.R. Squibb & Sons, L.L.C. $125.0001/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727943241 CMS
E.R. Squibb & Sons, L.L.C. $250.0001/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727943245 CMS
Daiichi Sankyo Inc. $1,562.5001/16/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739478063 CMS
Daiichi Sankyo Inc. $1,250.0001/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739477759 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $97,234.92 64
PY2020 $142,330.66 61
PY2021 $116,180.25 39
PY2022 $72,784.57 33
PY2023 $76,051.25 40
PY2024 $70,256.00 54
PY2025 $72,775.05 43

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,435.51 10
PY2025 Principal investigator $283,056.70 184
PY2024 Recipient $6,826.25 5
PY2024 Principal investigator $494,228.24 333
PY2023 Recipient $3,999.73 11
PY2023 Principal investigator $931,023.16 337
PY2022 Recipient $13,163.58 6
PY2022 Principal investigator $814,300.06 106
PY2021 Recipient $2,540.00 4
PY2021 Principal investigator $1,221,809.96 118
PY2020 Recipient $12,584.66 9
PY2020 Principal investigator $1,301,976.75 138
PY2019 Principal investigator $1,621,742.22 126

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

194 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533613
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533617
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533619
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533621
Principal investigator 1 ABBVIE INC. $410.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533789
Principal investigator 1 ABBVIE INC. $220.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533791
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533793
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533795
Principal investigator 1 ABBVIE INC. $64.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533797
Principal investigator 1 ABBVIE INC. $390.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533801
Principal investigator 1 ABBVIE INC. $64.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533843
Principal investigator 1 ABBVIE INC. $410.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533845
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533847
Principal investigator 1 ABBVIE INC. $220.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533849
Principal investigator 1 ABBVIE INC. $64.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533969
Principal investigator 1 ABBVIE INC. $64.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533971
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533973
Principal investigator 1 ABBVIE INC. $390.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533975
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533977
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533979
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533981
Principal investigator 1 ABBVIE INC. $64.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533983
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533985
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533987
Principal investigator 1 ABBVIE INC. $307.20 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533989
Principal investigator 1 ABBVIE INC. $410.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202533991
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
UNIVERSITY OF COLORADO DENVER SCHOOL OF MEDICINE
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1202533993
Principal investigator 1 ABBVIE INC. $90.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202534817
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202534833
Principal investigator 1 ABBVIE INC. $2,597.12 12/30/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202532184
Principal investigator 1 ABBVIE INC. $5,387.72 12/23/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202531756
Principal investigator 1 ABBVIE INC. $1,766.40 12/22/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531596
Principal investigator 1 ABBVIE INC. $2,444.80 12/22/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531622
Principal investigator 1 ABBVIE INC. $705.28 12/18/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202531076
Recipient ABBVIE INC. $725.00 12/01/2025 Covered Recipient Physician Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202397492
Principal investigator 1 ABBVIE INC. $2,444.80 11/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525800
Principal investigator 1 ABBVIE INC. $1,766.40 11/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525816
Principal investigator 1 Genentech, Inc. $14,673.46 11/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640923
Principal investigator 1 ABBVIE INC. $491.52 11/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525142
Principal investigator 1 ABBVIE INC. $1,013.76 11/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525144
Principal investigator 1 ABBVIE INC. $2,112.00 11/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202525146
Recipient ABBVIE INC. $1,450.00 11/05/2025 Covered Recipient Physician A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202397489
Recipient F. Hoffmann-La Roche AG $2.01 10/29/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211535325
Principal investigator 1 ABBVIE INC. $1,766.40 10/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518505
Principal investigator 1 ABBVIE INC. $2,444.80 10/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518513
Principal investigator 1 ABBVIE INC. $1,766.40 10/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518515
Principal investigator 1 ABBVIE INC. $2,444.80 10/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518653
Recipient F. Hoffmann-La Roche AG $0.53 10/23/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211535330
Recipient F. Hoffmann-La Roche AG $0.47 10/23/2025 Covered Recipient Physician Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211535334
Principal investigator 1 ABBVIE INC. $2,112.00 10/22/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202517763
Principal investigator 1 ABBVIE INC. $491.52 10/22/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202518049
Principal investigator 1 ABBVIE INC. $2,188.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516781
Principal investigator 1 ABBVIE INC. $2,500.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516783
Principal investigator 1 ABBVIE INC. $390.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516785
Principal investigator 1 ABBVIE INC. $390.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516787
Principal investigator 1 ABBVIE INC. $660.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516789
Principal investigator 1 ABBVIE INC. $410.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516791
Principal investigator 1 ABBVIE INC. $450.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516793
Principal investigator 1 ABBVIE INC. $510.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516795
Principal investigator 1 ABBVIE INC. $350.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516847
Principal investigator 1 ABBVIE INC. $90.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516849
Principal investigator 1 ABBVIE INC. $390.00 10/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202516851
Principal investigator 1 ABBVIE INC. $1,013.76 10/03/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202513233
Principal investigator 1 ABBVIE INC. $1,766.40 09/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512684
Principal investigator 1 ABBVIE INC. $2,444.80 09/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512696
Principal investigator 1 ABBVIE INC. $2,112.00 09/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512090
Principal investigator 1 ABBVIE INC. $491.52 09/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202512108
Principal investigator 1 ABBVIE INC. $714.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511652
Principal investigator 1 ABBVIE INC. $512.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511654
Principal investigator 1 ABBVIE INC. $1,536.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511664
Principal investigator 1 ABBVIE INC. $512.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511672
Principal investigator 1 ABBVIE INC. $102.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511674
Principal investigator 1 ABBVIE INC. $512.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511676
Principal investigator 1 ABBVIE INC. $512.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511682
Principal investigator 1 ABBVIE INC. $512.00 09/19/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202511684
Principal investigator 1 ABBVIE INC. $6,831.36 09/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202511066
Recipient ABBVIE INC. $1,087.50 09/11/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202397484
Principal investigator 1 ABBVIE INC. $2,301.44 09/10/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202510482
Principal investigator 1 ABBVIE INC. $2,353.92 09/10/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202510530
Recipient PFIZER INC. $940.00 09/09/2025 Covered Recipient Physician DACOMITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727693
Principal investigator 1 ABBVIE INC. $491.52 09/05/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202510174
Principal investigator 1 ABBVIE INC. $2,112.00 09/05/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202510190
Principal investigator 1 ABBVIE INC. $3,584.00 09/03/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202508134
Principal investigator 1 ABBVIE INC. $2,291.20 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506543
Principal investigator 1 ABBVIE INC. $2,534.40 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506545
Principal investigator 1 ABBVIE INC. $275.20 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506547
Principal investigator 1 ABBVIE INC. $2,124.80 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506549
Principal investigator 1 ABBVIE INC. $2,124.80 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506551
Principal investigator 1 ABBVIE INC. $134.40 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506553
Principal investigator 1 ABBVIE INC. $2,291.20 08/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202506555
Principal investigator 1 ABBVIE INC. $5,120.00 08/28/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202506437
Principal investigator 1 Genentech, Inc. $1,260.00 08/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640919
Principal investigator 1 ABBVIE INC. $31,584.00 08/06/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIV OF COLORADO
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202503203
Recipient ABBVIE INC. $1,450.00 08/01/2025 Covered Recipient Physician A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202397482
Principal investigator 1 ABBVIE INC. $3,072.00 08/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202500844
Principal investigator 1 ABBVIE INC. $4,096.00 07/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499906
Principal investigator 1 ABBVIE INC. $2,291.20 07/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499974
Principal investigator 1 ABBVIE INC. $410.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499428
Principal investigator 1 ABBVIE INC. $1,094.80 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499430
Principal investigator 1 ABBVIE INC. $1,094.80 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499434
Principal investigator 1 ABBVIE INC. $790.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499436
Principal investigator 1 ABBVIE INC. $1,094.80 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499438
Principal investigator 1 ABBVIE INC. $1,536.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499440
Principal investigator 1 ABBVIE INC. $1,524.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499442
Principal investigator 1 ABBVIE INC. $410.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499448
Principal investigator 1 ABBVIE INC. $1,030.80 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499450
Principal investigator 1 ABBVIE INC. $590.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499452
Principal investigator 1 ABBVIE INC. $500.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499454
Principal investigator 1 ABBVIE INC. $410.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202499456
Principal investigator 1 Genentech, Inc. $354.00 07/23/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640916
Principal investigator 1 ABBVIE INC. $416.01 07/16/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498314
Principal investigator 1 ABBVIE INC. $2,048.00 07/14/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202498124
Principal investigator 1 ABBVIE INC. $992.00 07/02/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing Recurrent Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1202495917
Principal investigator 1 ABBVIE INC. $2,291.20 06/26/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492981
Principal investigator 1 ABBVIE INC. $2,124.80 06/26/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492983
Principal investigator 1 ABBVIE INC. $2,291.20 06/26/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202493127
Principal investigator 1 ABBVIE INC. $500.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492463
Principal investigator 1 ABBVIE INC. $6,043.14 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492465
Principal investigator 1 ABBVIE INC. $64.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492467
Principal investigator 1 ABBVIE INC. $220.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492469
Principal investigator 1 ABBVIE INC. $500.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492471
Principal investigator 1 ABBVIE INC. $170.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492473
Principal investigator 1 ABBVIE INC. $64.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492487
Principal investigator 1 ABBVIE INC. $410.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492489
Principal investigator 1 ABBVIE INC. $90.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492491
Principal investigator 1 ABBVIE INC. $64.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492493
Principal investigator 1 ABBVIE INC. $90.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492503
Principal investigator 1 ABBVIE INC. $500.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492507
Principal investigator 1 ABBVIE INC. $307.00 06/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202492553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,508.16 06/12/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER No dispute reported 06/30/2026 1184206569
Principal investigator 1 Genentech, Inc. $3,989.00 06/09/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640902
Principal investigator 1 ABBVIE INC. $2,380.80 05/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486327
Principal investigator 1 ABBVIE INC. $2,124.80 05/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486329
Principal investigator 1 ABBVIE INC. $2,124.80 05/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202486331
Principal investigator 1 Genentech, Inc. $1,335.00 05/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640896
Principal investigator 1 Genentech, Inc. $1,105.65 05/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640907
Principal investigator 1 Genentech, Inc. $551.00 05/15/2025 Non-covered Recipient Entity
REGENTS OF THE UNIV OF COLORADO UNIV OF COLORADO DENVER GRANTS + CONTRACTS MS F428
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211640912
Principal investigator 1 ABBVIE INC. $806.40 04/30/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480203
Principal investigator 1 ABBVIE INC. $2,124.80 04/30/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480205
Principal investigator 1 ABBVIE INC. $2,291.20 04/30/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480239
Principal investigator 1 ABBVIE INC. $2,560.00 04/30/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202480267
Principal investigator 1 ABBVIE INC. $491.52 04/23/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202478476
Principal investigator 1 ABBVIE INC. $2,112.00 04/23/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202478487
Principal investigator 1 ABBVIE INC. $2,027.52 04/17/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202477204
Recipient PFIZER INC. $330.00 04/04/2025 Covered Recipient Physician ENCORAFENIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769297
Principal investigator 1 ABBVIE INC. $2,470.40 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467249
Principal investigator 1 ABBVIE INC. $2,291.20 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467449
Principal investigator 1 ABBVIE INC. $2,124.80 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467458
Principal investigator 1 ABBVIE INC. $806.40 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467463
Principal investigator 1 ABBVIE INC. $275.20 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467467
Principal investigator 1 ABBVIE INC. $2,124.80 03/31/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202467487
Principal investigator 1 ABBVIE INC. $390.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465357
Principal investigator 1 ABBVIE INC. $220.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465362
Principal investigator 1 ABBVIE INC. $850.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465365
Principal investigator 1 ABBVIE INC. $390.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465369
Principal investigator 1 ABBVIE INC. $550.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465373
Principal investigator 1 ABBVIE INC. $8,550.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465377
Principal investigator 1 ABBVIE INC. $1,660.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465380
Principal investigator 1 ABBVIE INC. $220.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465384
Principal investigator 1 ABBVIE INC. $820.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465388
Principal investigator 1 ABBVIE INC. $1,660.00 03/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202465395
Principal investigator 1 ABBVIE INC. $512.00 03/12/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202462800
Principal investigator 1 ABBVIE INC. $2,291.20 02/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455160
Principal investigator 1 ABBVIE INC. $2,124.80 02/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455164
Principal investigator 1 ABBVIE INC. $3,846.40 02/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455168
Principal investigator 1 ABBVIE INC. $1,036.80 02/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455175
Principal investigator 1 ABBVIE INC. $947.20 02/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202455179
Principal investigator 1 ABBVIE INC. $64.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454851
Principal investigator 1 ABBVIE INC. $3,280.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454863
Principal investigator 1 ABBVIE INC. $390.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454867
Principal investigator 1 ABBVIE INC. $220.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454872
Principal investigator 1 ABBVIE INC. $50.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454880
Principal investigator 1 ABBVIE INC. $390.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454884
Principal investigator 1 ABBVIE INC. $307.20 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454888
Principal investigator 1 ABBVIE INC. $2,220.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454901
Principal investigator 1 ABBVIE INC. $390.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454904
Principal investigator 1 ABBVIE INC. $540.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454911
Principal investigator 1 ABBVIE INC. $220.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454916
Principal investigator 1 ABBVIE INC. $1,560.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454920
Principal investigator 1 ABBVIE INC. $128.00 02/27/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202454924
Principal investigator 1 ABBVIE INC. $798.72 02/21/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202453538
Recipient ABBVIE INC. $1,450.00 02/19/2025 Covered Recipient Physician A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No dispute reported 06/30/2026 1202397480
Principal investigator 1 Genentech, Inc. $6,028.00 02/19/2025 Non-covered Recipient Entity
UNIVERSITY OF COLORADO GRANTS & CONTRACTS
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211677809
Principal investigator 1 Genentech, Inc. $1,105.65 02/12/2025 Non-covered Recipient Entity
UNIVERSITY OF COLORADO GRANTS & CONTRACTS
Open labelled randomized Alectinib VS crizotinib NSCLC 1L phase III trial No dispute reported 06/30/2026 1211677811
Principal investigator 1 ABBVIE INC. $2,675.20 02/10/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202450405
Principal investigator 1 ABBVIE INC. $2,124.80 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442353
Principal investigator 1 ABBVIE INC. $2,380.80 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442357
Principal investigator 1 ABBVIE INC. $2,560.00 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442361
Principal investigator 1 ABBVIE INC. $806.40 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442366
Principal investigator 1 ABBVIE INC. $4,823.04 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442369
Principal investigator 1 ABBVIE INC. $806.40 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442373
Principal investigator 1 ABBVIE INC. $2,534.40 01/29/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202442378
Principal investigator 1 ABBVIE INC. $243.69 01/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440221
Principal investigator 1 ABBVIE INC. $243.70 01/20/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF COLORADO
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202440233